Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Ravaud A, de la Fouchardière C, Caron P, Doussau A, Do Cao C, Asselineau J, Rodien P, Pouessel D, Nicolli-Sire P, Klein M, Bournaud-Salinas C, Wemeau JL, Gimbert A, Picat MQ, Pedenon D, Digue L, Daste A, Catargi B, Delord JP. Ravaud A, et al. Among authors: de la fouchardiere c. Eur J Cancer. 2017 May;76:110-117. doi: 10.1016/j.ejca.2017.01.029. Epub 2017 Mar 20. Eur J Cancer. 2017. PMID: 28301826 Clinical Trial.
Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort.
Roth GS, Fayet Y, Benmameche-Medjahed S, Ducimetière F, Charreton A, Cropet C, Chabaud S, Marion-Audibert AM, Berthelet O, Walter T, Adham M, Baconnier M, Tavan D, Williet N, Artru P, Huet-Penz F, Ray-Coquard I, Farsi F, Labrosse H, de la Fouchardière C. Roth GS, et al. Among authors: de la fouchardiere c. Cancers (Basel). 2022 Nov 3;14(21):5413. doi: 10.3390/cancers14215413. Cancers (Basel). 2022. PMID: 36358831 Free PMC article.
Results of combined treatment of anaplastic thyroid carcinoma (ATC).
Derbel O, Limem S, Ségura-Ferlay C, Lifante JC, Carrie C, Peix JL, Borson-Chazot F, Bournaud C, Droz JP, de la Fouchardière C. Derbel O, et al. Among authors: de la fouchardiere c. BMC Cancer. 2011 Nov 1;11:469. doi: 10.1186/1471-2407-11-469. BMC Cancer. 2011. PMID: 22044775 Free PMC article.
Combination chemotherapy in advanced adrenocortical carcinoma.
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group. Fassnacht M, et al. Among authors: de la fouchardiere c. N Engl J Med. 2012 Jun 7;366(23):2189-97. doi: 10.1056/NEJMoa1200966. Epub 2012 May 2. N Engl J Med. 2012. PMID: 22551107 Free article. Clinical Trial.
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ. Leboulleux S, et al. Among authors: de la fouchardiere c. Lancet Oncol. 2012 Sep;13(9):897-905. doi: 10.1016/S1470-2045(12)70335-2. Epub 2012 Aug 14. Lancet Oncol. 2012. PMID: 22898678 Clinical Trial.
One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma.
Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, de la Fouchardiere C, Libé R, Do Cao C, Niccoli P, Tabarin A, Raingeard I, Chougnet C, Giraud S, Gimenez-Roqueplo AP, Young J, Borson-Chazot F, Bertherat J, Wemeau JL, Bertagna X, Plouin PF, Schlumberger M, Baudin E; French group of Endocrine and Adrenal tumors (Groupe des Tumeurs Endocrines-REseau NAtional des Tumeurs ENdocrines and COrtico-MEdullo Tumeurs Endocrines networks). Hescot S, et al. Among authors: de la fouchardiere c. J Clin Endocrinol Metab. 2013 Oct;98(10):4006-12. doi: 10.1210/jc.2013-1907. Epub 2013 Jul 24. J Clin Endocrinol Metab. 2013. PMID: 23884775
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet AL, Do Cao C, Chougnet CN, Leboulleux S, Baudin E, Schlumberger M, de la Fouchardière C. Massicotte MH, et al. Among authors: de la fouchardiere c. Eur J Endocrinol. 2014 Mar 8;170(4):575-82. doi: 10.1530/EJE-13-0825. Print 2014 Apr. Eur J Endocrinol. 2014. PMID: 24424318
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; DECISION investigators. Brose MS, et al. Among authors: de la fouchardiere c. Lancet. 2014 Jul 26;384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24. Lancet. 2014. PMID: 24768112 Free PMC article. Clinical Trial.
Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.
de la Fouchardiere C, Oussaid N, Derbel O, Decaussin-Petrucci M, Fondrevelle ME, Wang Q, Bringuier PP, Bournaud-Salinas C, Peix JL, Lifante JC, Giraudet AL, Lopez J, Borson-Chazot F. de la Fouchardiere C, et al. Target Oncol. 2016 Feb;11(1):71-82. doi: 10.1007/s11523-015-0380-y. Target Oncol. 2016. PMID: 26285789
161 results